Last data update: Jun 24, 2024. (Total: 47078 publications since 2009)
Records 1-4 (of 4 Records) |
Query Trace: Jarrett OD [original query] |
---|
Pregnancy outcomes among women receiving rVSVDelta-ZEBOV-GP Ebola vaccine during the Sierra Leone Trial to introduce a vaccine against Ebola
Legardy-Williams JK , Carter RJ , Goldstein ST , Jarrett OD , Szefer E , Fombah AE , Tinker SC , Samai M , Mahon BE . Emerg Infect Dis 2020 26 (3) 541-548 Little information exists regarding Ebola vaccine rVSVDeltaG-ZEBOV-GP and pregnancy. The Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) randomized participants without blinding to immediate or deferred (18-24 weeks postenrollment) vaccination. Pregnancy was an exclusion criterion, but 84 women were inadvertently vaccinated in early pregnancy or became pregnant <60 days after vaccination or enrollment. Among immediate vaccinated women, 45% (14/31) reported pregnancy loss, compared with 33% (11/33) of unvaccinated women with contemporaneous pregnancies (relative risk 1.35, 95% CI 0.73-2.52). Pregnancy loss was similar among women with higher risk for vaccine viremia (conception before or <14 days after vaccination) (44% [4/9]) and women with lower risk (conception >15 days after vaccination) (45% [10/22]). No congenital anomalies were detected among 44 live-born infants examined. These data highlight the need for Ebola vaccination decisions to balance the possible risk for an adverse pregnancy outcome with the risk for Ebola exposure. |
Health conditions in an adult population in Sierra Leone: Data reported from the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE)
Fombah AE , Goldstein ST , Jarrett OD , Jalloh MI , El-Khorazaty J , Lisk DR , Legardy-Williams J , Pratt DA , George PM , Russell JBW , Schrag SJ , Dawson P , Deen GF , Carr W , Lindblad R , James F , Bah MM , Yillia JF , Sandy JD , Turay PE , Conteh MA , Slutsker L , Mahon BE , Samai M , Seward JF . J Infect Dis 2018 217 S75-s80 Clinical Trials Registration: ClinicalTrials.gov [NCT02378753] and Pan African Clinical Trials Registry [PACTR201502001037220]. |
Monitoring serious adverse events in the Sierra Leone Trial to Introduce a Vaccine Against Ebola
Jarrett OD , Seward JF , Fombah AE , Lindblad R , Jalloh MI , El-Khorazaty J , Dawson P , Burton D , Zucker J , Carr W , Bah MM , Deen GF , George PM , James F , Lisk DR , Pratt D , Russell JBW , Sandy JD , Turay P , Hamel MJ , Schrag SJ , Walker RE , Samai M , Goldstein ST . J Infect Dis 2018 217 S24-s32 Clinical Trials Registration: ClinicalTrials.gov [NCT02378753] and Pan African Clinical Trials Registry [PACTR201502001037220]. |
The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An evaluation of rVSVG-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak
Samai M , Seward JF , Goldstein ST , Mahon BE , Lisk DR , Widdowson MA , Jalloh MI , Schrag SJ , Idriss A , Carter RJ , Dawson P , Kargbo SAS , Leigh B , Bawoh M , Legardy-Williams J , Deen G , Carr W , Callis A , Lindblad R , Russell JBW , Petrie CR , Fombah AE , Kargbo B , McDonald W , Jarrett OD , Walker RE , Gargiullo P , Bash-Taqi D , Gibson L , Fofanah AB , Schuchat A . J Infect Dis 2018 217 S6-s15 Clinical Trials Registration: ClinicalTrials.gov [NCT02378753] and Pan African Clinical Trials Registry [PACTR201502001037220]. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Jun 24, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure